Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
9 Apr 24
DEF 14A
Definitive proxy
9 Apr 24
8-K
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
19 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Departure of Directors or Certain Officers
11 Jan 24
8-K
Relmada Therapeutics Provides Corporate Update
4 Jan 24
8-K
Departure of Directors or Certain Officers
3 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
8 Nov 23
8-K
Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting® 2023
11 Oct 23
8-K
Targeting Major Advances in the Treatment of CNS Disorders October 10 th , 2023
10 Oct 23
8-K
Targeting Major Advances in the Treatment of CNS Disorders October 4 th , 2023
4 Oct 23
8-K
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder
20 Sep 23
8-K
Departure of Directors or Certain Officers
6 Sep 23
8-K
Targeting Major Advances in the Treatment of CNS Disorders August 10 th , 2023
10 Aug 23
8-K
Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
S-8
Registration of securities for employees
21 Jun 23
8-K
Departure of Directors or Certain Officers
25 May 23
8-K
Targeting Major Advances in the Treatment of CNS Disorders May 15 th , 2023
15 May 23
8-K
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Targeting Major Advances in the Treatment of CNS Disorders April 19th, 2023
19 Apr 23
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEF 14A
Definitive proxy
31 Mar 23
10-K
2022 FY
Annual report
23 Mar 23
8-K
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results
23 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Entry into a Material Definitive Agreement
13 Jan 23
8-K
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O’Gorman MD as Chief Medical Officer
9 Jan 23
8-K
Entry into a Material Definitive Agreement
5 Jan 23
8-K
Entry into a Material Definitive Agreement
28 Dec 22
8-K
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I
7 Dec 22
8-K
Other Events
14 Nov 22
8-K
Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
10 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Relmada Therapeutics Announces Top-line Results from Phase 3
13 Oct 22
8-K
Entry into a Material Definitive Agreement
22 Sep 22
8-K
Other Events
20 Sep 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
Latest ownership filings
SC 13G/A
PERCEPTIVE ADVISORS LLC
6 Mar 24
144
Notice of proposed sale of securities
20 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
4
SERGIO TRAVERSA
31 Jan 24
4
Maged Shenouda
31 Jan 24
4
Chuck Ence
31 Jan 24
4
SERGIO TRAVERSA
19 Dec 23
4
Maged Shenouda
19 Dec 23
4
Paul Edward Kelly
19 Dec 23
4
JOHN GLASSPOOL
19 Dec 23
4
Fabiana Fedeli
19 Dec 23
4
Chuck Ence
19 Dec 23
4
CHARLES J CASAMENTO
19 Dec 23
SC 13G/A
BlackRock Inc.
7 Jul 23
4
SERGIO TRAVERSA
30 May 23
4
Maged Shenouda
30 May 23
4
ERIC THOMAS SCHMIDT
30 May 23
4
Paul Edward Kelly
30 May 23
4
JOHN GLASSPOOL
30 May 23
4
Fabiana Fedeli
30 May 23
4
Chuck Ence
30 May 23
4
CHARLES J CASAMENTO
30 May 23
4
Cedric O'Gorman
24 May 23
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 23
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Deep Track Capital, LP
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G
VANGUARD GROUP INC
9 Feb 23
5/A
SERGIO TRAVERSA
6 Feb 23
5
SERGIO TRAVERSA
2 Feb 23
5
Paul Edward Kelly
2 Feb 23
5
CHARLES J CASAMENTO
2 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
3
Fabiana Fedeli
13 Jan 23
4
Cedric O'Gorman
13 Jan 23
3
Cedric O'Gorman
13 Jan 23